The Journal of clinical endocrinology and metabolism
-
J. Clin. Endocrinol. Metab. · Apr 2011
Randomized Controlled Trial Multicenter StudyEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. ⋯ In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.
-
J. Clin. Endocrinol. Metab. · Mar 2011
Editorial CommentThe dynamic incretin adaptation and type 2 diabetes.
-
J. Clin. Endocrinol. Metab. · Feb 2011
Randomized Controlled Trial Multicenter StudyAlendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited. ⋯ Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes.
-
J. Clin. Endocrinol. Metab. · Feb 2011
Multicenter StudyEffect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. ⋯ In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.
-
J. Clin. Endocrinol. Metab. · Feb 2011
Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome.
Women with polycystic ovary syndrome (PCOS) are insulin resistant and have a high risk of early-onset diabetes and cardiovascular disease. Obstructive sleep apnea (OSA) has adverse cardiometabolic consequences and is highly prevalent in women with PCOS. We sought to determine whether continuous positive airway pressure (CPAP) treatment of OSA has beneficial effects on cardiometabolic function in PCOS. ⋯ In young obese women with PCOS, successful treatment of OSA improves insulin sensitivity, decreases sympathetic output, and reduces diastolic blood pressure. The magnitude of these beneficial effects is modulated by the hours of CPAP use and the degree of obesity.